టాక్సికాలజీ: ఓపెన్ యాక్సెస్

నైరూప్య

Tolerance of Tyrosine Kinase Inhibitors among 33 Cancer Patients Followed in CHU Annaba-Algeria

Soudani W, Djafer R, Djeddi H, Boughrira S and Griffi F

Background: The Inhibitors of Tyrosine Kinase are new targeted therapy recently explored with an aim of increasing the selectivity of antitumor action, the main objective was to evaluate the tolerance with the Inhibitors of Tyrosine Kinase among cancer patients.

Material and Methods: A descriptive and retrospective study was carried out into a series of thirty-three case (33) cancer patients reached of chronic myeloid leukemia followed on the service of Hemato-oncology CHU Annaba in Algeria during December 2013 to April 2014.

Results and Discussion: The study of the tolerance showed that Imatinib (Glivec®) gave only one case with complications colopathy type and respiratory allergy with disappearance of the osseous pains and the arterial hypertension obtained with Imatinib(Imatib®); what confirms a good tolerance of the specialty of Glivec® compared to Imatib®.We did not note any complication for Dasatinib and Nilotinib, with reduction in the specific undesirable effects (Dasatinib gave 16.67% of the osseous pains, Nilotinib 9.09% of osseous pains and 9.09% of myalgia), reduction in the asthenia (33.33% for Dasatinib and 9.09% for Nilotinib), this testifies to a better tolerance of the new molecules Tyrosine kinase inhibitors Dasatinib and Nilotinib compared to the molecule of reference Imatinib.

Conclusion: Through these data we raise the interest of selection of the therapeutic protocols and the importance of a strict monitoring of the undesirable effects of targeted therapy in order to ensure the best taken in charge for these patients.